Buprenorphine Hydrochloride

Parsippany, N.J., Jan. 7, 2026 /PRNewswire/ -- Dexcel Pharma USA is excited to announce the successful closing of an Asset Purchase Agreement with Orexo AB to acquire the U.S. rights to Zubsolv® (buprenorphine and naloxone) sublingual tablets and the associated commercial infrastructure. This acquisition is an important milestone in the Company's history, as it provides us with new capabilities to promote branded products. Continue Reading Zubsolv Logo Our CEO, Doug Boothe, added: "Dexcel Pharma is excited to be adding the Zubsolv® product and related commercial capabilities from Orexo into our expanding US operations. This product, together with our proven sales & marketing platform, will enable Dexcel Pharma's strategic growth in the U.S." The Company thanks its employees and third-party advisors, including DLA Piper LLP (US) for their hard work and support in connection with this transaction. We look forward to working with new and existing customers and partners to ensure continued access to this important therapy in the treatment of opioid use disorder. For more information please visit About Dexcel Pharma USA Dexcel Pharma USA is the U.S. subsidiary of Dexcel Pharma. Dexcel Pharma is the largest private pharmaceutical company in Israel, commercializing an extensive portfolio of branded and generic drugs. Our state-of-the-art R&D and manufacturing facilities enable us to develop and manufacture high-quality products while maintaining long-term partnerships across the value chain. SOURCE Dexcel Pharma USA 21% more press release views with Request a Demo

WEDNESDAY, Dec. 3, 2025 -- Buprenorphine adherence among youths may prevent overdose, emergency department use, and hospitalization, according to a study published online Nov. 18 in Pediatrics . Scott E. Hadland, M.D., M.P.H., from Mass General Brigham for Children in Boston, and colleagues conducted a retrospective cohort analysis using 2014 to 2022 data from the Massachusetts Public Health Data Warehouse to examine patterns of duration/adherence to buprenorphine and associations with subsequent overdose, emergency department use, and hospitalization among youth aged 13 to 26 years initiating buprenorphine. Data were included for 11,649 Massachusetts youth initiating buprenorphine (60.3 percent male; 85.9 percent non-Hispanic White; 55.4 percent enrolled in Medicaid). The researchers identified four patterns of medication use: high adherence for 12 months, low adherence for 12 months, discontinuation in three to nine months, and discontinuation in less than three months (23.7, 27.5, 16.4, and 32.5 percent, respectively). Overall, 5.0 and 6.6 percent of youth switched to methadone and naltrexone, respectively. Overdose risk was higher for lower adherence for 12 months, discontinuation in three to nine months, and discontinuation in less than three months compared with high adherence for 12 months (adjusted hazard ratios, 1.46, 1.82, and 1.76, respectively). Low adherence and discontinuation in less than three months led to a higher risk for emergency department use compared with high adherence, and a higher risk for hospitalization was seen for other trajectories compared with high adherence. "Our findings suggest that maintaining high adherence for at least a year substantially reduces overdose risk," Hadland said in a statement. "It's a clear message to clinicians, families and youth that longer treatment saves lives." One author disclosed ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required)